Plavix(R) Indications Expanded in Japan to Include
Patients with Acute Coronary Syndrome for Whom Percutaneous
Coronary Intervention Is Being Planned
<strong><br /></strong>PARIS- Oct. 21 /PRNewswire / --Sanofi-aventis announced today that the Japanese Ministry ofHealth- Labor and Welfare (MHLW) has granted approval for aSupplemental New Drug Application (sNDA) for the indication of"Acute coronary syndrome (unstable angina pectoris- non-STelevation myocardial infarction) for which percutaneous coronaryintervention (PCI) is being planned" for Plavix(R)(clopidogrel).